v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company has defined its Chief Operating Decision Maker (“CODM”) as the Executive Chairman. The CODM manages the Company’s operations as a single operating segment, which comprises its single reportable segment, for the purposes of assessing performance and making operating decisions. The Company’s focus is on the research, development and commercialization of novel therapeutics for the treatment of rare diseases. The Company’s research, development and commercialization efforts are focused on its lead molecule, mavorixafor, which is being marketed in the U.S. under the trade name XOLREMDI. The CODM uses the Company’s condensed consolidated net loss to monitor actual results as compared to forecast in assessing segment performance and allocation of resources.

The Company derives its revenue from the sale of XOLREMDI in the U.S. and from licensed rights and product sales of mavorixafor for other non-U.S. territories. The Company recognized $2.4 million and $4.8 million of revenue from its U.S. customer and $6.4 million and $6.7 million of revenue from a customer in the United Kingdom for the three and six months ended June 30, 2026, respectively. The Company recognized $1.7 million and $2.7 million of revenue from its U.S. customer and $0.2 million and $28.1 million of revenue from its customer in the United Kingdom for the three and six months ended June 30, 2025, respectively.

The measure of profit for the segment is net loss and consisted of the following for the three and six months ended June 30, 2026, and 2025:
Three Months Ended June 30,Six Months Ended June 30,
(in thousands)2026202520262025
Revenue from external customers $8,806 $1,973 $11,514 $30,780 
Compensation expense, excluding stock-based compensation, stock appreciation rights compensation expense and severance expense4,820 9,903 9,900 21,473 
Direct research and development program expenses (X4P-001, mavorixafor) 10,428 9,413 20,824 17,825 
Other segment items (a)9,715 8,398 17,188 16,941 
Net loss (measure of segment profit)$(16,157)$(25,741)$(36,398)$(25,459)
(a) Other segment items primarily include cost of revenue, non-compensation departmental costs within sales, general and administrative departments, certain unallocated external costs within research and development, stock-based compensation expense, stock appreciation rights compensation expense, severance expense, other income (expense), and provision for income taxes.

The CODM only receives and reviews information regarding segment assets at the consolidated level. Certain other entity-wide disclosures are included elsewhere in these condensed consolidated financial statements. As of June 30, 2026, the Company’s single operating segment had long-lived assets, including property and equipment and right-of-use assets, of $0.8 million, which were located in the U.S. As of December 31, 2025, the operating segment’s long-lived assets were $1.6 million, all of which were located in the U.S.